Milestone Re-Profiling.
Cancer adapts to survive. Your intelligence must adapt faster.
A genomic test gives you a highly accurate snapshot of your cancer on the day the blood was drawn. But cancer is a living, evolving system. When you attack a tumour with targeted therapies, the cancer actively tries to find a bypass. Over months of treatment, it sheds its old vulnerabilities and develops entirely new genetic mutations to survive. This is known clinically as Clonal Evolution.
If your oncologist is making Line 2 or Line 3 treatment decisions based on a genomic report from a year ago, they are fighting a ghost. They are treating what the cancer was, not what it has become.
Onkommon Track is a scheduled, comprehensive molecular re-profiling program. By taking a broad, 118-gene read of your cancer's DNA at major clinical milestones, we catch the exact new mutations the cancer has acquired, opening up entirely new drug options and trial matches before standard scans even realize the current treatment has stopped working.
Track what your cancer has become.
A scheduled, comprehensive re-profiling program that catches new mutations at critical milestones — unlocking new drug options and trial matches.
- 118-Gene Read: Complete re-profiling of your cancer's evolving DNA
- Milestone Timing: Strategically scheduled at 0, 3, 6 months and line changes
- Clonal Evolution Analysis: See exactly which new mutations are driving growth
- Fresh Drug Match Table: New mutations mean new options
- Treatment Evolution Report: Detailed map for your oncologist
The core problem.
Why relying on a single, historical genomic test limits your survival options.
The Bypass Effect
You start a highly effective targeted drug. For six months, the tumour shrinks. But quietly, a fraction of the cancer cells mutate, creating a "bypass track" that allows them to ignore the drug and grow again.
The Blind Spot
If you only use standard monitoring, you will eventually see the tumour growing again on a scan. But you won't know why.
The Track Advantage
By doing a complete 118-gene re-read of your blood (ctDNA) at regular intervals, we don't just see that the cancer is growing — we see exactly which new mutation is driving the growth. This gives your oncologist the precise target they need to switch your drug immediately.
Understanding the difference.
We offer two distinct forms of continuous monitoring. They work beautifully together, but serve entirely different clinical purposes.
Sentinel
Sentinel is a highly frequent, narrow test. It looks only at the specific mutations we already know your tumour has. It is designed to act as an early warning system, catching rising ctDNA levels between major doctor visits.
- Frequent blood draws (every 4–8 weeks)
- Narrow focus — known mutations only
- Early warning for recurrence or resistance
Track
Track is done less frequently (at major milestones), but it is a massive, comprehensive sweep. We re-read a full 118 genes to see if entirely new mutations have appeared that Sentinel wasn't looking for.
- Scheduled at major clinical milestones
- 118-gene comprehensive sweep
- Catches entirely new mutations
💡 Maximum Intelligence
Many advanced patients use a combination of both — Track at 0, 3, and 6 months to map the landscape, and Sentinel in between to monitor the day-to-day signals.
When do we test?
Track is not random. It is strategically timed to align with the critical junctures in your treatment journey.
The Baseline
At the absolute start of your journey, before Line 1 treatment begins. (This also serves as the required baseline for Sentinel).
⬇️The 3-Month Check
To evaluate early molecular response to the therapy. Is the cancer responding at the DNA level?
⬇️The 6-Month Check
The critical juncture where acquired resistance commonly begins to form. This is where we catch the bypass tracks.
⬇️Line Changes
Any time your oncologist confirms that a current treatment has clinically failed, a Track draw should immediately be done before choosing the next therapy.
What you get.
Cancer evolution requires continuous data. We bundle our testing to ensure you are covered across the timeline of your treatment.
A comprehensive re-profiling package designed to follow you through the most critical phases of your first year of treatment.
- The 118-Gene Sweep: Every single draw is a complete run of our advanced Signature Baseline liquid biopsy panel.
- Clonal Evolution Analysis: Our AI and clinical team computationally compare Draw 2 and Draw 3 directly against your Baseline, isolating the exact new mutations the cancer has acquired.
- Fresh Intelligence on Every Draw: New mutations mean new options. With every draw, you receive a completely refreshed Indian Drug-Match Table and a newly updated Clinical Trial Eligibility screen based on the cancer's new profile.
- Treatment Evolution Report: A dedicated report for your oncologist detailing exactly how the cancer's architecture has shifted.
Can't commit to the full bundle? If you need a single 118-gene read, you can purchase the Signature Baseline test individually for ₹2,50,000. However, the Track bundle (₹5,50,000 for 3 draws) is heavily subsidised to encourage continuous monitoring, which our clinical team believes is the most effective way to manage advanced cancer.
KCCIRC Clinic Wing
While Onkommon Track provides your current treating doctor with a real-time map of how your cancer is evolving, an acquired resistance mutation might prompt you to seek a new medical perspective.
If Track detects that your cancer has mutated and you require a formal, medical second opinion on how to alter your treatment line, Onkommon is proud to partner directly with the KCCIRC Clinic Wing.
You can choose to seamlessly transition your Track evolution data to the KCCIRC multidisciplinary tumour board for a formal clinical review and a direct treatment prescription for your next line of therapy.
Please note: A formal medical consultation with KCCIRC doctors is a separate clinical service billed in addition to your Track testing.
KCCIRC Multidisciplinary Tumour Board
Led by senior oncologists, our tumour board reviews complex clonal evolution data with the full weight of clinical expertise — delivering a formal written opinion on your next line of therapy.
Delhi & SikkimFrequently Asked Questions
Everything you need to know about Onkommon Track.
A massive 523-gene test (like our Signature Complete CGP) is incredibly powerful for finding initial targets, especially in Stage 4 cancers. However, testing 523 genes once does not tell you how the cancer adapts 6 months later. Track uses a highly focused 118-gene panel repeated multiple times, which is mathematically superior for tracking acquired resistance over time.
Track is conducted entirely via Liquid Biopsy (a simple blood draw). This is critical, as asking a patient to undergo a painful, invasive surgical tissue biopsy every 3 months just to check for new mutations is clinically unviable. Blood draws capture the real-time DNA shedding from the tumour seamlessly.
If you need a single 118-gene read, you can purchase the Signature Baseline test individually for ₹2,50,000. However, the Track bundle (₹5,50,000 for 3 draws) is heavily subsidised to encourage continuous monitoring, which our clinical team believes is the most effective way to manage advanced cancer.
If a Track draw discovers that your cancer has developed a new resistance mutation, it triggers our clinical intelligence protocol. We instantly cross-reference that new mutation against global databases to find the specific next-line therapies, biosimilars, or active India clinical trials engineered to target it, arming your doctor with an immediate pivot strategy.